StockNews.com upgraded shares of Prime Medicine (NYSE:PRME – Free Report) to a sell rating in a report published on Saturday morning.
A number of other equities analysts also recently issued reports on the company. TD Cowen began coverage on Prime Medicine in a research report on Monday, April 8th. They set a buy rating for the company. Wedbush restated an outperform rating and set a $12.00 price objective on shares of Prime Medicine in a research report on Tuesday, April 23rd. Chardan Capital started coverage on Prime Medicine in a report on Monday, April 22nd. They issued a buy rating and a $17.00 target price for the company. Citigroup upgraded Prime Medicine from a neutral rating to a buy rating and set a $10.00 target price for the company in a report on Thursday, May 16th. Finally, HC Wainwright started coverage on Prime Medicine in a report on Monday, May 20th. They issued a buy rating and a $10.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $15.09.
View Our Latest Stock Analysis on Prime Medicine
Prime Medicine Trading Down 0.7 %
Prime Medicine (NYSE:PRME – Get Free Report) last issued its quarterly earnings data on Friday, May 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. The company had revenue of $0.59 million for the quarter. On average, sell-side analysts predict that Prime Medicine will post -1.64 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the stock. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in shares of Prime Medicine during the second quarter valued at approximately $97,000. ARK Investment Management LLC boosted its position in shares of Prime Medicine by 2.2% during the second quarter. ARK Investment Management LLC now owns 6,126,773 shares of the company’s stock valued at $31,492,000 after buying an additional 133,419 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Prime Medicine by 61.0% during the second quarter. Bank of New York Mellon Corp now owns 170,563 shares of the company’s stock valued at $877,000 after buying an additional 64,600 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Prime Medicine by 22,652.9% during the second quarter. Nisa Investment Advisors LLC now owns 7,736 shares of the company’s stock valued at $40,000 after buying an additional 7,702 shares during the last quarter. Finally, ORG Partners LLC purchased a new position in shares of Prime Medicine during the second quarter valued at approximately $29,000. Hedge funds and other institutional investors own 70.37% of the company’s stock.
Prime Medicine Company Profile
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
Read More
- Five stocks we like better than Prime Medicine
- Conference Calls and Individual Investors
- Survey: Top 175 Fittest Retirement Locations in America
- Trading Stocks: RSI and Why it’s Useful
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Roth IRA Calculator: Calculate Your Potential Returns
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.